Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ZVSA
ZVSA | US
0.23
USD-0.03
-11.50%
ZVSA | US
About ZVSA
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
09/03/2026
Close
0.23
Open
0.26
High
0.26
Low
0.23
ZyVersa Therapeutics Inc. a clinical stage biopharmaceutical company develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200 a cholesterol efflux mediator which is in Phase 2a clinical trial to the treatment of multiple renal indications such as focal segmental glomerulosclerosis alport syndrome and diabetic nephropathy; and IC 100 a monoclonal antibody inflammasome ASC inhibitor that is in preclinical stage for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics Inc. is headquartered in Weston Florida.
View LessZVSA | US
Risk
142.2
Sharpe
-0.40
Luna's Score
40/100
Recommendation
Sell
Luna says (ZVSA | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
Price Below SMA10D
High 6-Month Volatility (>65%)
Microcap (<300M USD)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
94.4%1 month
142.2%3 months
176.6%6 months
145.6%Returns
Fundamental Ratios
PE
0.00
Fwd. PE
-
Price to book
0.29
Debt to equity
-
Debt to assets
-
Ent. to EBITDA
-2.21
Ent. to rev.
-
PEG
-
Other Fundamentals
EBITDA
-10.25M
MarketCap
247.17K
MarketCap(USD)
247.17K
Div. yield
-
Op. margin
-
Erngs. growth
-
Rev. growth
-
Ret. on equity
-152.23
Short ratio
0.32
Short perc.
2.22
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.05
Range1M
0.12
Range3M
0.17
Volumes: Market Activity
Rel. volume
1.21
Price X volume
10.45K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -2.21 | 0.53 | Cheaper |
| Ent. to Revenue | - | 3,967.00 | - |
| PE Ratio | 0.00 | 41.03 | Cheaper |
| Price to Book | 0.29 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 176.56 | 72.80 | Riskier |
| Debt to Equity | - | -1.23 | - |
| Debt to Assets | - | 0.25 | - |
| Market Cap | 247.17K | 3.66B | Emerging |
